How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management
Open Access
- 29 October 2022
- journal article
- research article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 25 (1) , 12-33
Abstract
Purpose: This review aims at investigating pathophysiological mechanisms in spondyloarthritis (SpA). Analysis of genetic factors, immunological pathways, and abnormalities of bone metabolism lay the foundations for a better understanding of development of the axial clinical manifestations in patients, allowing physician to choose the most appropriate therapeutic strategy in a more targeted manner. Recent Findings: In addition to the contribution of MHC system, findings emerged about the role of non-HLA genes (as ERAP1 and 2, whose inhibition could represent a new therapeutic approach) and of epigenetic mechanisms that regulate the expression of genes involved in SpA pathogenesis. Increasing evidence of bone metabolism abnormalities secondary to the activation of immunological pathways suggests the development of various bone anomalies that are present in axSpA patients. Summary: SpA are a group of inflammatory diseases with a multifactorial origin, whose pathogenesis is linked to the genetic predisposition, the action of environmental risk factors, and the activation of immune response. It is now well known how bone metabolism leads to long-term structural damage via increased bone turnover, bone loss and osteoporosis, osteitis, erosions, osteosclerosis, and osteoproliferation. These effects can exist in the same patient over time or even simultaneously. Evidence suggests a cross relationship among innate immunity, autoimmunity, and bone remodeling in SpA, making treatment approach a challenge for rheumatologists. Specifically, treatment targets are consistently increasing as new drugs are upcoming. Both biological and targeted synthetic drugs are promising in terms of their efficacy and safety profile in patients affected by SpA.Keywords
Funding Information
- Università degli Studi di Roma Tor Vergata
This publication has 214 references indexed in Scilit:
- Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociNature Genetics, 2013
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Annals of the Rheumatic Diseases, 2013
- Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursorsArthritis Research & Therapy, 2010
- Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility lociNature Genetics, 2010
- Quantitative Trait Loci for CD4:CD8 Lymphocyte Ratio Are Associated with Risk of Type 1 Diabetes and HIV-1 Immune ControlThe American Journal of Human Genetics, 2010
- The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammationNature Immunology, 2009
- Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variantsNature Genetics, 2007
- Treatment of ankylosing spondylitis with pamidronate: an open label studyAnnals of the Rheumatic Diseases, 2006
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984
- Histopathology of the synovial membrane of peripheral joints in ankylosing spondylitis.Annals of the Rheumatic Diseases, 1982